Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

SQI Diagnostics Inc V.SQD.H

SQI Diagnostics Inc. is a Canada-based company that is focused on lung health. The Company is engaged in the development and manufacturing of respiratory health and precision medicine tests that run on its fully automated systems. Its clinical solutions include Rapid Acute Lung Injury Diagnostic (RALI-Dx), lung transplant diagnostics, COVID-19 testing and surveillance testing solutions. Its RALI-Dx IL-6 Severity Triage Test and the RALI-fast IL-6 Severity Triage point of care (POC) Test each help clinicians identify which patients with SARS-CoV-2 are predicted to have a severe inflammatory response and should or should not be admitted to the hospital. Its RALI-Dx delivers results from the lab in less than an hour while RALI-fast delivers results at the patient point-of-care in about 15 minutes. The Company’s TORdx LUNG Test measures inflammation at the molecular level to assess the health of the donor lung. The Company is also focused on its organ transplant pipeline of products.


TSXV:SQD.H - Post by User

Post by FactFinder1994on Mar 15, 2022 2:32pm
118 Views
Post# 34515962

Roche Diagnostic Head sees....

Roche Diagnostic Head sees....

In the long run, Schinecker sees a new testing market emerging from COVID. People have grown accustomed to testing when they have a respiratory illness, and they’ll want to continue that post-pandemic. Roche is already rolling out a combination COVID-influenza rapid antigen test, for instance.

“It won’t be COVID only; it’ll be more like a respiratory market,” Schinecker said—and a market worth “single digit billions,” he figures.

......now if you follow SQI closely you will understand that SQI is all over this market.  Here below is most recent Investor Presentation for quick reference.  Check out pages 24 & 33 for more detail on the Rali-Dx and Rali-fast.  

SQI Diagnostics Inc Corporate Information 2022
 

<< Previous
Bullboard Posts
Next >>